Secretoneurin, an Angiogenic Neuropeptide, Induces Postnatal Vasculogenesis

Background—Induction of postnatal vasculogenesis, the mobilization of bone marrow–derived endothelial progenitor cells and incorporation of these cells into sites of blood vessel formation, is a well-known feature of angiogenic cytokines such as vascular endothelial growth factor. We hypothesized that the angiogenic neuropeptide secretoneurin induces this kind of neovascularization. Methods and Results—Secretoneurin induced mobilization of endothelial progenitor cells to sites of vasculogenesis in vivo in the cornea neovascularization assay. Progenitor cells were incorporated into vascular structures or were located adjacent to them. Systemic injection of secretoneurin led to increase of circulating stem cells and endothelial progenitor cells. In vitro secretoneurin induced migration, exerted antiapoptotic effects, and increased the number of these cells. Furthermore, secretoneurin stimulated the mitogen-activated protein kinase system, as shown by phosphorylation of extracellular signal–regulated kinase, and activated the protein kinase B/Akt pathway. Activation of mitogen-activated protein kinase was necessary for increase of cell number and migration, whereas Akt seemed to play a role in migration of endothelial progenitor cells. Conclusions—These data show that the angiogenic neuropeptide secretoneurin stimulates postnatal vasculogenesis by mobilization, migration, and incorporation of endothelial progenitor cells.

[1]  Douglas Losordo,et al.  The Neuropeptide Secretoneurin Acts as a Direct Angiogenic Cytokine In Vitro and In Vivo , 2004, Circulation.

[2]  D. Fliser,et al.  Erythropoietin regulates endothelial progenitor cells. , 2004, Blood.

[3]  C. Heeschen,et al.  Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. , 2003, Blood.

[4]  U. Laufs,et al.  Intravenous Transfusion of Endothelial Progenitor Cells Reduces Neointima Formation After Vascular Injury , 2003, Circulation research.

[5]  L. Naldini,et al.  Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells , 2003, Nature Medicine.

[6]  Shahin Rafii,et al.  Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration , 2003, Nature Medicine.

[7]  G. Gurtner,et al.  Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures , 2002, Circulation.

[8]  Rachel Jones.  Prefrontal cortex: One step at a time? , 2002, Nature Reviews Neuroscience.

[9]  M. Salis,et al.  Nerve Growth Factor Promotes Angiogenesis and Arteriogenesis in Ischemic Hindlimbs , 2002, Circulation.

[10]  M. Sands,et al.  VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K. Shimada,et al.  Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial , 2002, The Lancet.

[12]  S. Rafii,et al.  Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment , 2002, Nature Medicine.

[13]  J. Isner,et al.  Statin Therapy Accelerates Reendothelialization: A Novel Effect Involving Mobilization and Incorporation of Bone Marrow-Derived Endothelial Progenitor Cells , 2002, Circulation.

[14]  David J. Anderson,et al.  Sensory Nerves Determine the Pattern of Arterial Differentiation and Blood Vessel Branching in the Skin , 2002, Cell.

[15]  C. Verfaillie,et al.  Origin of endothelial progenitors in human postnatal bone marrow. , 2002, The Journal of clinical investigation.

[16]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[17]  J. Isner,et al.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. , 2001, The Journal of clinical investigation.

[18]  A M Zeiher,et al.  HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. , 2001, The Journal of clinical investigation.

[19]  S. Fichtlscherer,et al.  Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease , 2001, Circulation research.

[20]  E. Topol,et al.  Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling. , 2001, Circulation research.

[21]  J. Isner,et al.  Reversal of experimental diabetic neuropathy by VEGF gene transfer. , 2001, The Journal of clinical investigation.

[22]  J. Alroy,et al.  Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy , 2000, Nature Medicine.

[23]  J. Isner,et al.  Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  G. Lundborg,et al.  Vascular Endothelial Growth Factor Has Neurotrophic Activity and Stimulates Axonal Outgrowth, Enhancing Cell Survival and Schwann Cell Proliferation in the Peripheral Nervous System , 1999, The Journal of Neuroscience.

[25]  J. Isner,et al.  VEGF contributes to postnatal neovascularization by mobilizing bone marrow‐derived endothelial progenitor cells , 1999, The EMBO journal.

[26]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[27]  W. T. Chen,et al.  Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. , 1998, Circulation research.

[28]  S. Rafii,et al.  Evidence for circulating bone marrow-derived endothelial cells. , 1998, Blood.

[29]  W. Prodinger,et al.  Differential chemotactic activities of sensory neuropeptides for human peripheral blood mononuclear cells. , 1997, Journal of immunology.

[30]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[31]  A. Laslop,et al.  Secretogranin II: Molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin , 1995, Progress in Neurobiology.

[32]  R. Kirchmair,et al.  Secretoneurin—a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C) , 1993, Neuroscience.

[33]  J. C. Tony.  The chromogranin-secretogranin family. , 2003, The New England journal of medicine.

[34]  A. Laslop,et al.  Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. , 2000, The Journal of clinical endocrinology and metabolism.